Breast Cancer Clinical Trials in New York

Showing 61-80 of 838 trials

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

NCT05095207

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Breast CancerMetastasis

Icahn School of Medicine at Mount Sinai42 participantsStarted Sep 2021

New York, New York, United States • New York, New York, United States • New York, New York, United States

RECRUITINGPhase 1< 1 mile

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Iambic Therapeutics, Inc383 participantsStarted Mar 2024

La Jolla, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +45 more locations

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Breast Cancer Trials in Other Cities

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

A Study of Language Interpretation Solutions for People With Breast Cancer

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Breast Cancer Implementation Science Study With Educational Intervention

Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Combination Study of SV-BR-1-GM With Retifanlimab

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Other Conditions in New York